Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) than the standard twice-daily inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination of budesonide plus formoterol (Symbicort). This was among the findings of a post-hoc analysis of the FULFIL trial presented at CHEST 2021, the American College of Chest Physicians annual meeting. Study author, Reynold Panettieri Jr., MD, vice chancellor for Translational Medicine and science director of Rutgers Institute for Translational Medicine in New Brunswick, New Jersey, discusses the findings and clinical implications of the analysis. To read the full story.
Triple Therapy Effective for Severe COPD Exacerbations.
